Torrey Loper
Poor outcomes and high mortality are possible costs of delayed care for untreated patients with severe structural heart disease.
Reducing variability in care for this patient population is critical to early identification and improving patient outcomes…
Reducing variability in care for this patient population is critical to early identification and improving patient outcomes…
On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.
© 2025 egnite, Inc. All Rights Reserved. egnite, egnite Inc., CardioCare, the heart logo, and the spark logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.
Privacy Policy Intellectual Property Terms of Use Implementation Kit Careers